Partnerships & Alliances

Found 54,226 articles

• 

  Boehringer Ingelheim to Mine Ginkgo’s Molecules in $406M Undruggable Targets ...

  5/8/2023

  Partnership seeks to identify novel therapeutic molecules to address diseases with high unmet patient needs. It’s the second target discovery company to link with BI in the last month.

• Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases

  5/8/2023

  Life Biosciences and Forge Biologics today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications.

• Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China

  5/8/2023

  Chance Pharmaceuticals and Acorda Therapeutics, Inc. today announced that they have entered into distribution and supply agreements to provide INBRIJA ® in Greater China (Mainland China , Taiwan , Hong Kong , and Macao ). INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.

• CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

  5/8/2023

  CureVac N.V. today announced that the first participant was dosed in the Phase 1 part of a combined Phase 1/2 study of multivalent, modified mRNA seasonal flu vaccine candidates, developed in collaboration with GSK.

• Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Diseases

  5/8/2023

  Ginkgo Bioworks today announced a new partnership with Boehringer Ingelheim.

• Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China

  5/8/2023

  Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Hangzhou Chance Pharmaceuticals Co. Ltd. today announced that they have entered into distribution and supply agreements to provide INBRIJA ® in China.

• BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company’s Phase 2 Clinical Trial

  5/8/2023

  BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that it has signed a clinical trial agreement with Northwell Health, New York State's largest health care provider and private employer, and Northwell’s Feinstein Institutes for Medical Research.

• Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023

  5/8/2023

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals today will deliver a podium presentation of its research titled "Impact of Rifaximin Use During The 30-Day Post-Discharge Period Following an Overt Hepatic Encephalopathy Hospitalization on Healthcare Utilization And Costs" during Digestive Disease Week® (DDW) 2023, which will be held virtually and in-person in Chicago, IL through Tuesday, May 9, 2023.

• Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™

  5/8/2023

  Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting.

• Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome

  5/5/2023

  Aditxt®, Inc. today announces that its subsidiary Adimune™, Inc. (“Adimune”), has signed a clinical trial agreement with Mayo Clinic to advance clinical studies targeting autoimmune diseases.

• Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

  5/4/2023

  Adagene Inc. announced achievement of a milestone in its ongoing collaboration with Exelixis for development of novel masked antibody-drug conjugate candidates leveraging Adagene’s proprietary SAFEbody precision masking technology.

• MODERNA AND NOVOCOL PHARMA ANNOUNCE FILL-FINISH AGREEMENT FOR CANADIAN-MADE MRNA VACCINES

  5/4/2023

  Moderna, Inc. (NASDAQ: MRNA) today announced a long-term agreement with Ontario-based Novocol Pharma, a leading sterile injectable contract development and manufacturing organization (CDMO), to perform aseptic fill-finish, labelling and packaging of mRNA respiratory vaccines expected to be produced in Canada.

• MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform

  5/4/2023

  MaxCyte, Inc. today announced the signing of a strategic platform license (SPL) with Walking Fish Therapeutics , Inc. a biotechnology company that is rapidly advancing B cell-based therapeutics.

• TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory Diseases

  5/4/2023

  TFF Pharmaceuticals, Inc. today announced that it has entered into a Collaborative Research and Development Agreement (CRADA) with the National Institute of Environmental Health Sciences (NIEHS) to develop respirable, dry powder formulations of high molecular weight hyaluronan (HMW-HA) for treating or preventing respiratory diseases.

• Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration

  5/4/2023

  Silence Therapeutics plc today announced that AstraZeneca has nominated the first product candidate under its siRNA (short interfering RNA) collaboration and will pay Silence a $10 million option fee to advance development on an undisclosed program.

• OncoHost Collaborates with BGN Technologies to Predict Cancer Patient Response to Anti-PD-1 Treatment with IcAR Biosensing Tech

  5/4/2023

  OncoHost today announced that it has signed an option agreement with BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev (BGU), to receive a license for a novel biosensing technology called IcAR (Immuno-checkpoint Artificial Reporter). IcAR was developed by a team of researchers from BGU.

• Artificial intelligence identifies anti-aging drug candidates targeting ‘zombie’ cells

  5/4/2023

  Integrated Biosciences in collaboration with researchers at the Massachusetts Institute of Technology and the Broad Institute of MIT and Harvard, announced results demonstrating the power of artificial intelligence to discover novel senolytic compounds, a class of small molecules under intense study for their ability to suppress age-related processes such as fibrosis, inflammation and cancer.

• Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb

  5/4/2023

  Amphista Therapeutics today announced the delivery of the first discovery milestone under its collaboration and license agreement with Bristol Myers Squibb, triggering a payment for achieving the milestone.

• Forge Biologics and Labcorp Announce Strategic AAV Gene Therapy Development and Manufacturing Collaboration

  5/3/2023

  Forge Biologics, a leading manufacturer of genetic medicines, today announced a gene therapy development and manufacturing collaboration with Labcorp (NYSE: LH), a leading global life sciences company.

• LABCORP AND JEFFERSON HEALTH ANNOUNCE STRATEGIC LABORATORY RELATIONSHIP

  5/3/2023

  Labcorp (NYSE: LH), a leading global life sciences company, today announced an agreement to enter into a strategic relationship with Jefferson Health (Jefferson), the largest health system serving the greater Philadelphia area and Southern New Jersey.